- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
回复 tlyuhq 的帖子
我向HBF询问了此查询, 他们的回覆:
简而言之,迄今为止,尚无已知数据引起美国目前批准的疫苗对公众或患有肝病(包括乙型肝炎)的疫苗的安全性的担忧。 如果一个人患有乙型肝炎,并且没有免疫力低下,那么他们将像没有肝病的同龄人一样对疫苗产生反应。
In brief, to date there is no known data that raises concerns about the safety of the currently approved vaccines in the United States for the general public, or for those with liver disease (including hepatitis B). If an individual has hepatitis B, and not immunocompromised, they are expected to respond to the vaccine as their peers without liver disease.
HBF科学和医学咨询委员会刚刚发表了一份声明,说明针对SARS CoV-2(引起COVID-19)的新疫苗。 谨附上该声明,供您参考和参考。 现在它也已发布在我们的网站上。
https://www.hepb.org/news-and-ev ... atitis-b-community/
当然,中国的疫苗不同于欧美的疫苗.疫苗本身是病毒的蛋白质或产生蛋白质的RNA, 没有免疫刺激作用. 但是使用的佐剂可能有刺激作用
HBF Scientific and Medical Advisory Board has just issued a statement about the new vaccines against SARS CoV-2 (that causes COVID-19). I am attaching the statement for your reference and information. It is also now posted here on our website. |
|